Abstract:Abstract Background Faecal calprotectin (FC) is of value in differentiating Inflammatory Bowel Disease (IBD) from other causes of lower gastrointestinal (GI) symptoms and is recommended in national guidance. This study aims to examine the role of and factors associated with faecal calprotectin requesting in primary care. Methods Retrospective open cohort study using Clinical Practice Research Datalink (CPRD Aurum) of adults aged 18 years and above with lower GI symptoms between 2015 and 2019. FC requested 30 days before to 3 months after a lower GI symptom record in primary care were included. Logistic regression model was used to explore patient level factors associated with FC testing. Referral pathways and outcomes in terms of IBD diagnoses of patients with and without FC testing were also examined. Results Of 741,190 symptomatic patients, only 18,320 (2.5%) patients had a FC requested in primary care: median age 38.3 (IQR 28.9-50.7); 51.4% females. The percentage of FC requests in symptomatic patients increased from 0.02% in 2010 to 4.4% in 2019 (p=0.001). FC value of <50 ug/g and 50-200 ug/g were predominantly seen in patients with abdominal pain (42.1% and 37.9% respectively) while FC > 200 ug/g was predominantly seen in patients with diarrhoea (45.3%). The only patients with a significant risk of IBD with a FC 50-200ug/g were patients with rectal bleeding (8%). Factors associated with less FC requesting included: increasing age (>70 years aOR 0.16 ( 95% CI 0.15-0.18); female (0.89,0.86-0.92); Black (0.61, 0.56-0.66) or Asian (0.75, 0.70-0.80) ethnicity; obesity (0.89,0.85-0.93); lower socioeconomic status (0.91,0.86-0.98); comorbidity score >2 (0.73,0.68-0.79); and current smoking (0.89,0.85-0.92). Patients with change in bowel habit (7.31,6.90-7.75); rectal bleeding (2.04,1.95-2.13); diarrhoea (2.88,2.78-2.99) as a presenting symptom compared to abdominal pain and ex-smokers (1.06,1.03-1.11) had more FC requests. Of patients referred with a FC >200 ug/g, 21.5% were diagnosed with IBD but only 2.9% of patients with a FC 50-200ug/g. 27.8% patients with a normal FC test result were still referred to secondary care, of which only 0.4% had IBD. Conclusion Despite an increase in FC requests in recent years, only 4.4% of patients with relevant lower GI symptoms had an FC requested in primary care as recommended. Despite a negative FC test, 27.8% of patients were still referred to secondary care with very few patients diagnosed with IBD (0.4%).

Fecal Calprotectin Concentrations in Healthy Children Aged 1-18 Months

Fecal Calprotectin in Healthy Children Aged 1-4 Years

Fecal calprotecin levels and its trends in healthy 6~18 months old infants

Fecal Calprotectin Levels Are Higher in Rural Than in Urban Chinese Infants and Negatively Associated with Growth

Differences in fecal calprotectin levels of six-month-old infants in poor rural and affluent urban areas in China and its determinants

Comparison of the Different Kinds of Feeding on the Level of Fecal Calprotectin

Faecal calprotectin concentrations in apparently healthy children aged 0-12 years in urban Kampala, Uganda: a community-based survey

[Clinical Value of Hepatic Fibrosis Parameters and Serum Ferritin in Obese Children with Nonalcoholic Fatty Liver Disease].

Can Fecal Calprotectin Levels Be Used to Monitor Infant Milk Protein Allergies?

Exploring the Diagnostic Spectrum of Children with Raised Faecal Calprotectin Levels

Quantitative Relationship Between Liver Fat Content and Metabolic Syndrome in Obese Children and Adolescents.

[Epidemiologic Survey on the Prevalence and Distribution of Childhood Functional Constipation in the Northern Areas of China: a Population-Based Study].

The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee

Home‐based fecal calprotectin utilization in a general pediatric gastroenterology clinic

[Age Distribution Characteristics of Intestinal Segmented Filamentous Bacteria and Their Relationship with Intestinal Mucosal Immunity in Children].

Current status of fecal calprotectin as a diagnostic or monitoring biomarker for cow’s milk protein allergy in children: a scoping review

Fecal Calprotectin in Differential Diagnosis of Diarrhea

P364 Faecal calprotectin testing in patients presenting with lower gastrointestinal symptoms; a retrospective primary care study in the United Kingdom

Assessing the correlation between fecal calprotectin, blood markers and disease activity in pediatric inflammatory bowel disease

Characterization of Fecal Microbiota, Short-Chain Fatty Acids and Lactic Acid Concentrations in 5-8-year-old Children with Cow Milk Protein Allergy

Diagnostic Accuracy of Fecal Calprotectin in Discriminating Organic-Inflammatory Gastrointestinal Diseases and Functional Gastrointestinal Disorders in Older Patients